Lifeboat Foundation

Research published in The American Journal of Human Genetics has identified a previously unknown genetic link to autism spectrum disorder (ASD). The study found that variants in the DDX53 gene contribute to ASD, providing new insights into the genetic underpinnings of the condition.

ASD, which affects more males than females, encompasses a group of neurodevelopmental conditions that result in challenges related to communication, social understanding and behavior. While DDX53, located on the X chromosome, is known to play a role in brain development and function, it was not previously definitively associated with autism.

In the study, researchers from The Hospital for Sick Children (SickKids) in Canada and the Istituto Giannina Gaslini in Italy clinically tested 10 individuals with ASD from eight different families and found that variants in the DDX53 gene were maternally inherited and present in these individuals. Notably, the majority were male, highlighting the gene’s potential role in the male predominance observed in ASD.

FOR IMMEDIATE RELEASE

“High-Speed Sequential DNA Computing Using a Solid-State DNA Origami Register” ACS Central Science

DNA stores the instructions for life and, along with enzymes and other molecules, computes everything from hair color to risk of developing diseases. Harnessing that prowess and immense storage capacity could lead to DNA-based computers that are faster and smaller than today’s silicon-based versions. As a step toward that goal, researchers report in ACS Central Science a fast, sequential DNA computing method that is also rewritable — just like current computers.

The data shows that RNA interacts with a mitochondrial protein complex to trigger immune response pathways when viral RNA is present.

Penn Engineers have modified lipid nanoparticles (LNPs)—the revolutionary technology behind the COVID-19 mRNA vaccines—to not only cross the blood-brain barrier (BBB) but also to target specific types of cells, including neurons. This breakthrough marks a significant step toward potential next-generation treatments for neurological diseases like Alzheimer’s and Parkinson’s.

In a new paper in Nano Letters, the researchers demonstrate how peptides —short strings of amino acids —can serve as precise targeting molecules, enabling LNPs to deliver mRNA specifically to the endothelial cells that line the blood vessels of the brain, as well as neurons.

This represents an important advance in delivering mRNA to the cell types that would be key in treating neurodegenerative diseases; any such treatments will need to ensure that mRNA arrives at the correct location. Previous work by the same researchers proved that LNPs can cross the BBB and deliver mRNA to the brain, but did not attempt to control which cells the LNPs targeted.

Investigators from Cedars-Sinai and the University of California, San Francisco (UCSF) have identified a new way to deliver instructions that tell stem cells to grow into specific bodily structures, a critical step in eventually regenerating and repairing tissues and organs.

The scientists engineered cells that form structures called “synthetic organizers.” These organizers provided instructions to the stem cells through biochemical signals called morphogens, which stimulated and enabled the stem cells to grow into specific complex tissues and organ-like assemblies.

The research was conducted with mouse embryonic stem cells, and the findings were published in Cell.

Monitoring electrical signals in biological systems helps scientists understand how cells communicate, which can aid in the diagnosis and treatment of conditions like arrhythmia and Alzheimer’s.

But devices that record electrical signals in cell cultures and other liquid environments often use wires to connect each electrode on the device to its respective amplifier. Because only so many wires can be connected to the device, this restricts the number of recording sites, limiting the information that can be collected from cells.

MIT researchers have now developed a biosensing technique that eliminates the need for wires. Instead, tiny, wireless antennas use light to detect minute electrical signals.

Dr Torbjörn Ogéus is a pain specialist with clinical experience in regenerative medicine. He has been treating tendons and osteoarthritis (OA) with growth factors for 15 years. 6 years ago, Ogéus did his first stem cell treatment for OA and recently published one of the first clinical studies in the world on exosomes and OA.

A breakthrough in understanding how a single-cell parasite makes ergosterol (its version of cholesterol) could lead to more effective drugs for human leishmaniasis, a parasitic disease that afflicts about 1 million people and kills about 30,000 people around the world every year.

The findings, reported in Nature Communications, also solve a decades-long scientific puzzle that’s prevented drugmakers from successfully using azole antifungal drugs to treat visceral leishmaniasis, or VL.

About 30 years ago, scientists discovered the two species of single-cell parasites that cause VL, Leishmania donovani and Leishmania infantum, made the same lipid sterol, called ergosterol, as fungi proven susceptible to azoles antifungals. These azoles antifungals target a crucial enzyme for sterol biosynthesis, called CYP51.

A new type of norovirus is causing a very high number of cases in countries like England, just as a large trial of an mRNA vaccine is starting up.

By Michael Le Page